Pain Research and Treatment / 2018 / Article / Tab 2

Research Article

The Consumption of Cannabis by Fibromyalgia Patients in Israel

Table 2

Cannabis and other treatment related parameters of all participants.

ParameterResults (%)

(i) Total number of patients who uses cannabis323/383 (84)
(ii) No. of patients licensed for MC142/323 (44)
(iii) No. of patients who consume cannabis without a license181/323 (56)
(iv) No. of patients who applied for MC license317/383 (83)
(v) No. of patients who appealed after refusal65
(vi) No. of appeals prior to licensing
 127
 216
 310
(vii) No. of licensed patients reporting MC supplied not enough94/142 (66)
(viii) No. of licensed patients who buy in black market78/142 (55)
(ix) Amount of cannabis consumed/ month (g) by all the patients31.4±16.3, 5-150
(x) Amount of money paid for cannabis in the black market (US$)106±206, 29-1428
(xi) Frequency of cannabis consumption/day4.7±3.96, 1-20
(xii) No. of patients using ≥ 3 species of MC63/142 (~44)
(xiii) No. of patients using 2 species of MC50/142 (~35)
(xiv) No. of patients using 1 species of MC29/142 (~21)
(xv) Method of cannabis consumption by all participants
 Smoking with cigarette241/323 (63)
 Smoking pure cannabis85 (~17)
 Oil under tongue18 (~5)
 Vaporizing57 (~15)
(xvi) No. of patients reporting adverse effects from cannabis36/308 (12)
(xvii) No. of patients reporting feeling dependent on cannabis25/304 (8)
(xviii) No. of patients reporting adverse effects from regular meds for fibromyalgia prior to cannabis use336/357 (94)
(xix) No. of patients reporting dependence on regular meds229/348 (66)
(xx) Patients’ report on the use of other meds under cannabis
 Using the same other meds45/304 (15)
 Sopped all other meds134/304 (44)
 Consuming less other meds125/304 (41)

mean±SD, range.
No. = Number.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.